(Q35603779)

9 August 2017

1 reference

title

Basiliximab: a review of its use as induction therapy in renal transplantation. (English)

1 reference

9 August 2017

2

Gillian M Keating

1 reference

9 August 2017

Therese M Chapman

1

1 reference

9 August 2017

publication date

1 January 2003

1 reference

9 August 2017

1 reference

9 August 2017

volume

63

1 reference

9 August 2017

issue

24

1 reference

9 August 2017

page(s)

2803-2835

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200363240-00009

9 August 2017

exact match

0 references

cites work

Reducing adverse effects of immunosuppressive agents in kidney transplant recipients

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200363240-00009

Meta-analysis of basiliximab for immunoprophylaxis in renal transplantation

21 January 2018

1 reference

12 December 2020

Simulect, calcineurin inhibitor, mycophenolate mofetil, and prednisone is more effective than OKT3, calcineurin inhibitor, hycophendate mofetil, and prednisone in African American kidney recipients in reducing acute rejections and prolonging graft s

1 reference

12 December 2020

Basiliximab versus ATG/ALG induction in pediatric renal transplants: comparison of herpes virus profile and rejection rates

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of a chimeric interleukin-2 receptor monoclonal antibody, basiliximab, in renal transplantation: a comparison between Japanese and non-Japanese patients

1 reference

12 December 2020

Basiliximab induction improves the outcome of renal transplants in children and adolescents.

1 reference

12 December 2020

Absence of acute rejection using basiliximab with triple immunosuppression in cadaveric kidney recipients in first three months

1 reference

12 December 2020

Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation

1 reference

12 December 2020

Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients

1 reference

12 December 2020

Is complete avoidance of calcineurin inhibitors or steroids now possible? Importance of patient selection and choice of regimen

1 reference

12 December 2020

Efficacy and safety of basiliximab in pediatric renal transplantation

1 reference

12 December 2020

Within-patient controlled assessment of the influence of basiliximab on cyclosporine in pediatric de novo renal transplant recipients

1 reference

12 December 2020

Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation

1 reference

12 December 2020

Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. The U.S. Simulect Renal Transplant Study Group

1 reference

12 December 2020

Simulect, Neoral, Cellcept, and prednisone in kidney recipients with delayed graft function: a prospective controlled study

1 reference

12 December 2020

A calcineurin antagonist-free induction strategy for immunosuppression in cadaveric kidney transplant recipients at risk for delayed graft function

1 reference

12 December 2020

Potential of daclizumab in solid organ transplantation

1 reference

12 December 2020

International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology

1 reference

12 December 2020

Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group

1 reference

12 December 2020

Prolonged immunosuppressive effect and minimal immunogenicity from chimeric (CD25) monoclonal antibody SDZ CHI 621 in renal transplantation

1 reference

12 December 2020

Induction immunosuppression with interleukin-2 receptor antibodies (basiliximab and daclizumab) in renal transplant recipients

1 reference

12 December 2020

Interleukin-2 receptor antibody-induced alterations of ciclosporin dose requirements in paediatric transplant recipients

1 reference

12 December 2020

Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy.

1 reference

12 December 2020

Cost evaluation of basiliximab treatment for renal transplant patients in Japan

1 reference

12 December 2020

Renal transplantation with Simulect (basiliximab) plus Sandimmune Neoral-based immunosuppression: a report of 41 cases in Taiwan

1 reference

12 December 2020

Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation

1 reference

12 December 2020

Cost-minimization study comparing Simulect versus Thymoglobulin in renal transplant induction

1 reference

12 December 2020

Inhibition of the IL-15 pathway in anti-CD25 mAb treated renal allograft recipients

1 reference

12 December 2020

Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group

1 reference

12 December 2020

Experience with basiliximab in pediatric renal transplantation

1 reference

12 December 2020

Simulect (basiliximab) reduces acute cellular rejection in renal allografts from cadaveric and living donors

1 reference

12 December 2020

Renal transplantation in adults

1 reference

12 December 2020

Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts

1 reference

12 December 2020

Overview of transplantation immunology and the pharmacotherapy of adult solid organ transplant recipients: focus on immunosuppression

1 reference

12 December 2020

Basiliximab-sirolimus-prednisone induction regimen followed by delayed low-dose cyclosporine in renal transplant recipients of living donors

1 reference

12 December 2020

The Banff 97 working classification of renal allograft pathology

1 reference

12 December 2020

Duration of action of a chimeric interleukin-2 receptor monoclonal antibody, basiliximab, in pediatric kidney transplant recipients

1 reference

12 December 2020

Simulect: redefining immunosuppressive strategies

1 reference

12 December 2020

Screening for basiliximab exposure-response relationships in renal allotransplantation

1 reference

12 December 2020

A single center experience with basiliximab induction therapy in renal transplantation

1 reference

12 December 2020

Economic analysis of basiliximab in renal transplantation

1 reference

12 December 2020

Daclizumab: a review of its use in the management of organ transplantation

1 reference

12 December 2020

The IL2 pathway in clinical immunosuppression

1 reference

12 December 2020

A multicenter, open-label, pharmacokinetic/pharmacodynamic safety, and tolerability study of basiliximab (Simulect) in pediatric de novo renal transplant recipients

1 reference

12 December 2020

A rational dosing algorithm for basiliximab (Simulect) in pediatric renal transplantation based on pharmacokinetic-dynamic evaluations.

1 reference

12 December 2020

The economics of basiliximab (Simulect) in preventing acute rejection in renal transplantation.

1 reference

12 December 2020

A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients

1 reference

12 December 2020

A prospective economic evaluation of basiliximab (Simulect) therapy following renal transplantation

1 reference

12 December 2020

Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection

1 reference

12 December 2020

An economic and quality-of-life assessment of basiliximab vs antithymocyte globulin immunoprophylaxis in renal transplantation

1 reference

12 December 2020

Pharmacoeconomic evaluation of Simulect prophylaxis in renal transplant recipients.

1 reference

12 December 2020

Reduced acute rejection and superior 1-year renal allograft survival with basiliximab in patients with diabetes mellitus. The Global Simulect Study Group

1 reference

12 December 2020

Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials

1 reference

12 December 2020

Induction strategy using basiliximab combined with mycophenolate MMF and immediate low-dose cyclosporin is steroid sparing and more effective than OKT3.

1 reference

12 December 2020

Efficacy and tolerability of interleukin-2 receptor blockade with basiliximab in pediatric renal transplant recipients

1 reference

12 December 2020

Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil

1 reference

12 December 2020

Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection

1 reference

12 December 2020

Basiliximab reduces the incidence of acute cellular rejection in live-related-donor kidney transplantation: a three-year prospective randomized trial.

1 reference

12 December 2020

Prevention of transplant rejection: current treatment guidelines and future developments

1 reference

12 December 2020

Single centre experience with basiliximab in paediatric renal transplantation

1 reference

12 December 2020

Clinically significant drug interaction between basiliximab and tacrolimus in renal transplant recipients

1 reference

12 December 2020

Improved graft survival after renal transplantation in the United States, 1988 to 1996

1 reference

12 December 2020

Role of anti-interleukin-2 receptor antibodies in kidney transplantation

1 reference

12 December 2020

10.2165/00003495-200363240-00009

Identifiers

DOI

1 reference

Dimensions Publication ID

9 August 2017

1025746439

0 references

1 reference